• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gsk Plc ADR (NY: GSK )

    37.01 UNCHANGED
    Streaming Delayed Price Updated: 7:00 PM EDT, Oct 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Gsk Plc ADR

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    35 36 Next >
    GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests
    New research suggests that GSK's Shingrix vaccine may reduce dementia risk, potentially revolutionizing treatment for older adults. The study, involving 200,000 people, indicates a significant... 
    Via Benzinga
    Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
    ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient... 
    Via Benzinga
    3 Stocks Under $10 With the Potential for Massive Gains
    Discover the growth potential of top small-cap stocks in the consumer finance, healthcare equipment and pharmaceutical industries. 
    Via InvestorPlace
    Top Research Reports For Apple, Lowe's & Shopify
    Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., Lowe's Companies, Inc., and Shopify Inc., as well as two micro-cap stocks MIND Technology, Inc., and... 
    Via Talk Markets
    European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
    European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed. 
    Via Benzinga
    Exposures COVID-19
    Is GSK a Top-Value Stock Right Now?
    GSK, a multinational pharma company, scans as a bargain. 
    Via The Motley Fool
    3 Top Cancer Treatment Stocks to Buy Now
    These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term. 
    Via InvestorPlace
    Positive News is Driving This Cancer Drug Maker’s Stock Higher
    IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
    Via MarketBeat
    The 3 Most Undervalued Pharma Stocks to Buy in July 2024
    Pharma stocks can be great investments during times of growth and recession, and are made even better if the stock is undervalued. 
    Via InvestorPlace
    Topics Economy
    Exposures Economy
    GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season
    From GSK plc
    Via Business Wire
    3 Dirt-Cheap Drug Developers With Blockbuster Potential
    These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent. 
    Via InvestorPlace
    Health Officials Keep Close Eye On Bird Flu As It Infects Cows For The First Time
    Avian influenza continues to spread among animals and has infected four dairy workers in the US. Concerns about human-to-human transmission are low. 
    Via Benzinga
    The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024
    A full-throated bull market makes it tough to find undervalued stocks under $50, but these three could soon lead the charge higher. 
    Via InvestorPlace
    Pfizer's RSV Vaccine Abrysvo Clears Concerns Over Preterm Birth Risk, Safety For Pregnant Women, New Study Shows
    Pfizer's RSV vaccine, Abrysvo, for pregnant women shows no increased risk of pre-term births, according to a study. Researchers found no significant difference in pre-term birth rates between... 
    Via Benzinga
    United Kingdom Stocks, ETFs To Watch After Keir Starmer, Labour Party Win
    New leadership in the United Kingdom could make several sectors standout going forward. Here's what experts are saying after the election. 
    Via Benzinga
    Topics ETFs
    Upcoming Stock Spinoffs: Should You Pounce or Pass?
    Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. 
    Via InvestorPlace
    CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts
    CureVac layoffs are coming for 30% of the vaccine company's employees as it prepares for a restructuring that will save it over 30% in costs. 
    Via InvestorPlace
    Topics Workforce
    Exposures Layoff
    CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK
    CureVac stock is up on Wednesday as CVAC investors react to the company signing a new 1.4 billion euro licensing agreement with GSK. 
    Via InvestorPlace
    GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
    GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gains full control of vaccine candidates for influenza and COVID-19, while... 
    Via Benzinga
    Exposures COVID-19
    3 No-Brainer Stocks to Buy With $300 Right Now for the Second Half of 2024
    A modest amount of money can go a long way when it's put to work in highly innovative, game-changing businesses. 
    Via The Motley Fool
    Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
    A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to proceed, with the companies needing Delaware Supreme Court approval to... 
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK
    The CDC's ACIP recommends RSV vaccines for adults 75+, and for those 60-74 with chronic conditions. GSK's Arexvy is approved for adults 50-59 at risk. A decision on adults 50-59 is pending further... 
    Via Benzinga
    Why Is Moderna Stock Trading Lower On Wednesday?
    The CDC's Advisory Committee on Immunization Practices is set to discuss recommendations for RSV, influenza, and COVID-19 vaccines. Moderna's data shows vaccine efficacy drops to 50% after 18 months in... 
    Via Benzinga
    Exposures COVID-19
    Moderna Crumbles After RSV Vaccine Effectiveness Pales Vs. Pfizer, GSK Shots
    After 18 months, Moderna's RSV vaccine proved about 50% effective against lower respiratory tract disease. 
    Via Investor's Business Daily
    Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
    Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners. 
    Via Benzinga
    UK Chooses Pfizer Over GSK for Multi-Million Dose RSV Vaccine Contract
    Pfizer secures a UK contract to supply millions of doses of its Abrysvo RSV vaccine, surpassing GSK's bid. The agreement includes doses for older adults and pregnant mothers. 
    Via Benzinga
    Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer
    GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threatens the state's business-friendly reputation and judicial consistency. 
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
    EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Death
    Exposures Death
    Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
    From FN Media Group LLC
    Via GlobeNewswire
    Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
    Discover Cantor Fitzgerald's analysis on Innoviva, highlighting its unique royalty-based business model with GSK for asthma and COPD products. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    35 36 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.